Edgar Lerma, MD, provides insights into the pathophysiology of IgA nephropathy (IgAN) and the therapeutic promise of ...
The US FDA has granted accelerated approval to atrasentan (Vanrafia) for reducing proteinuria in adults with primary ...
Zacks Investment Research on MSN2d
APLS' Empaveli sNDA for 2 Rare Kidney Diseases Gets FDA Priority TagApellis Pharmaceuticals APLS announced that the FDA has accepted its supplemental new drug application (sNDA) seeking the ...
More than one-third of patients with systemic lupus erythematosus experience a flare after starting dialysis for end-stage ...
The U.S. Food and Drug Administration (FDA) on Wednesday granted accelerated approval for Novartis AG’s (NYSE:NVS) Vanrafia ...
The supplemental New Drug Application for the C3G and IC-MPGN indications is supported by data from the phase 3 VALIANT study.
Vanrafia reduces proteinuria in adults with primary immunoglobulin A nephropathy (IgAN). It has a wholesale acquisition cost ...
Our kidneys take on the weighty need of filtrating virtually fifty gallons of blood on a daily basis. And, our eating habits do impose unperceived stress on these vital organs. Nowadays, the ...
CKD is responsible for chronic inflammation and oxidative stress and results in the build-up of uremic toxins, which ...
CHMP recommends approval for Averoa’s Xoanacyl, an oral therapy for chronic kidney disease: Grenoble, France Friday, April 4, 2025, 12:00 Hrs [IST] Averoa, a biopharmaceutical c ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback